Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

648 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status.
Loupakis F, Maddalena G, Depetris I, Murgioni S, Bergamo F, Dei Tos AP, Rugge M, Munari G, Nguyen A, Szeto C, Zagonel V, Lonardi S, Fassan M. Loupakis F, et al. Among authors: szeto c. J Immunother Cancer. 2019 Nov 8;7(1):297. doi: 10.1186/s40425-019-0788-5. J Immunother Cancer. 2019. PMID: 31703605 Free PMC article.
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
Schwartz S, Szeto C, Tian Y, Cecchi F, Corallo S, Calegari MA, Di Bartolomeo M, Morano F, Raimondi A, Fucà G, Martinetti A, De Pascalis I, Martini M, Belfiore A, Milione M, Orlandi A, Barault L, Barone C, de Braud F, Di Nicolantonio F, Benz S, Hembrough T, Pietrantonio F. Schwartz S, et al. Among authors: szeto c. Eur J Cancer. 2019 Jan;107:164-174. doi: 10.1016/j.ejca.2018.11.016. Epub 2018 Dec 19. Eur J Cancer. 2019. PMID: 30579113 Clinical Trial.
Safety, Feasibility, and Merits of Longitudinal Molecular Testing of Multiple Metastatic Sites to Inform mTNBC Patient Treatment in the Intensive Trial of Omics in Cancer.
Burton KA, Mahen E, Konnick EQ, Blau S, Dorschner MO, Ramirez AB, Schmechel SC, Song C, Parulkar R, Parker S, Senecal FM, Pritchard CC, Mecham BH, Szeto C, Spilman P, Zhu J, Gadi VK, Ronen R, Stilwell J, Kaldjian E, Dutkowski J, Benz SC, Rabizadeh S, Soon-Shiong P, Blau CA. Burton KA, et al. Among authors: szeto c. JCO Precis Oncol. 2022 Mar;6:e2100280. doi: 10.1200/PO.21.00280. JCO Precis Oncol. 2022. PMID: 35294224 Free PMC article. Clinical Trial.
The UCSC Cancer Genomics Browser: update 2011.
Sanborn JZ, Benz SC, Craft B, Szeto C, Kober KM, Meyer L, Vaske CJ, Goldman M, Smith KE, Kuhn RM, Karolchik D, Kent WJ, Stuart JM, Haussler D, Zhu J. Sanborn JZ, et al. Among authors: szeto c. Nucleic Acids Res. 2011 Jan;39(Database issue):D951-9. doi: 10.1093/nar/gkq1113. Epub 2010 Nov 8. Nucleic Acids Res. 2011. PMID: 21059681 Free PMC article.
The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex.
Jochems C, Tritsch SR, Knudson KM, Gameiro SR, Smalley Rumfield C, Pellom ST, Morillon YM, Newman R, Marcus W, Szeto C, Rabizadeh S, Wong HC, Soon-Shiong P, Schlom J. Jochems C, et al. Among authors: szeto c. Oncoimmunology. 2018 Nov 27;8(2):e1532764. doi: 10.1080/2162402X.2018.1532764. eCollection 2019. Oncoimmunology. 2018. PMID: 30713787 Free PMC article.
648 results